Canary Capital has registered a Delaware trust for a staked Injective (INJ) exchange-traded fund (ETF), signaling potential U.S. market entry for staking-focused cryptocurrency investment products. The trust, named ‘Canary Staked INJ ETF,’ aims to provide investors with exposure to staking rewards generated by the Injective blockchain.
This initiative forms part of Canary Capital’s broader strategy to introduce multiple staking-based ETFs. The firm has concurrently filed for similar products tracking Cronos (CRO), Sei (SEI), and Tron (TRX), reflecting growing institutional demand for yield-generating crypto assets.
The registration aligns with U.S. regulatory frameworks and could enable investors to access staking yields without direct token management responsibilities. This development highlights a market gap in the United States, where similar staking yield products like 21Shares’ Injective ETP already operate in European markets.
Canary Capital’s filings also include innovative proposals such as an ETF tracking the Pudgy Penguins ecosystem, which would combine exposure to governance tokens and non-fungible tokens (NFTs). These efforts collectively represent a significant expansion of structured crypto investment vehicles targeting staking rewards.